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Improved management of patients 
with osteoporosis
To the Editor: We commend Professor Davey’s pleas1 for greater 
awareness and improved management of patients suffering from 
osteoporosis or osteopenia and those with fragility fractures, 
particularly the elderly.
We contend that this disease is not optimally managed locally 
and is often still regarded as an inevitable part of the ageing process, 
not amenable to treatment. The facts that 20% of hip fracture 
victims die within one year of the event and that less than 50% are 
capable of leading an independent life are often ignored. Moreover, 
the fact that fracture risk can be halved when lifestyle measures 
and appropriate bone-active drugs are employed also seems to go 
unrecognised. The National Osteoporosis Foundation of South Africa 
(NOFSA) published a guideline on the diagnosis and management of 
osteoporosis in 2010 that is available in print and also freely available 
on our website, either as a full guideline or an executive summary.2
Unfortunately, osteoporosis medication is still not freely available 
to sufferers from this common disease, which affects one out of 
every four postmenopausal women and 20% of elderly men. The 
essential drugs list (EDL) published in June 20123 suggests that only 
patients with a bone mineral density (BMD) T-score of -2.5 standard 
deviation plus a fracture should be considered for treatment with 
bone-active medication. This is analogous to recommending that 
you should first have a stroke before your hypertension is eligible for 
treatment, or have a myocardial infarction before your dyslipidaemia 
is deserving of a statin! Clearly these EDL recommendations are 
embarrassingly out of touch with reality. There also appear to be 
regional differences in the availability of bone-active drugs in the 
public sector which is particularly problematic in the Western Cape, 
where NOFSA is frequently approached by patients and doctors unable 
to obtain justifiable osteoporosis treatment from a clinic or hospital. 
Moreover, unlike other provinces where access to modern intravenous 
bisphosphonates, strontium ranelate and even teriparatide can be 
obtained with or even without motivation, patients in the Western 
Cape are ‘fortunate’ when daily generic alendronate is made available – 
the efficacy and safety of which has been questioned.4-8
Access to osteoporosis medication is not only problematic in 
the public sector, however, and private patients, often the elderly 
and less wealthy, have similar problems. It is illogical that the 
test to diagnose the disease (dual-energy X-ray absorptiometry 
measurement of BMD) and the treatment of its complications (e.g. 
hip replacement) are readily reimbursed, yet its effective prevention 
is not. This is reminiscent of HIV/AIDS, the complications of which 
were treated for many years in this country before effective treatment 
of the disease itself was finally accepted and implemented. Unless 
one is on the very top tier of a medical aid scheme, funders do 
not usually reimburse osteoporosis medication. Since osteoporosis 
does not feature on the so-called Prescribed Minimum Benefits 
(PMB) list, medical aid schemes either refuse to pay or draw 
up their own arbitrary funding criteria and financially cap the 
reimbursement of osteoporosis treatment. This does not happen with 
other chronic non-communicable diseases. Patients are requested to 
make co-payments and the doctor’s ability to prescribe a particular 
drug is often severely limited, regardless of motivation and good 
scientific evidence of benefit. 
Several new osteoporosis drugs, ranging from specific 
monoclonal antibodies against RANKL (e.g. denosumab, 
already launched elsewhere)9 to inhibitors of cathepsin K (e.g. 
odanacatib)10 to potent bone formation stimulating agents (e.g. 
anti-sclerostin antibodies)11 will hit our markets in the foreseeable 
future, resulting in what Professor Davey terms ‘... widening the 
therapeutic horizons’. Although it might be a while before we have 
access to these exciting agents, it is NOFSA’s firm belief that every 
effort should be made to provide sufferers from this crippling 
disease rightful access to available effective therapy, in both the 
private and the public sectors.
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Can the re-engineering of PHC and/
or the introduction of community 
paediatricians be the solution?
To the Editor: The recent article about the new paediatric sub-specialty 
to improve child health in South Africa quotes grim child health 
statistics to illustrate the need to look for new strategies to improve 
child health.1 Can the re-engineering of primary healthcare (PHC) 
and/or the introduction of community paediatricians be the solution?
I would like to share my experience. We were also confronted 
with bad child health conditions and statistics, but achieved great 
improvement in one decade (Table 1).2-4
The improvement in maternal and child health was achieved by 
the vigorous implementation of PHC in the whole catchment area 
of the Gelukspan Community Hospital. The factors contributing 
to this achievement included a change from curative hospital-
based medicine to PHC; a determined effort to reach every child 
and pregnant woman in the community; comprehensive and 
integrated approach by the health services as a whole and no 
fragmentation; building a health team with strong reliance on 
nurses and allied health workers; and re-allocation of staff and 
resources to community-based services so that all villages had a 
clinic or visits by a mobile clinic.
During this time a visit to the hospital by the late Professor 
John Hansen during his sabbatical had a profound impact on 
the development of the services as a result of his enthusiasm and 
encouragement. However, the work was done by the PHC team 
816  November 2012, Vol. 102, No. 11  SAMJ
Correspondence
without any specialist doctors or nurses, and with involvement of the 
mothers as ‘the most important health workers’.
A similar remarkable improvement in maternal and child health 
recently reported from India was achieved by a nurse-driven 
programme and strong focus on community involvement.5 Maternal 
mortality decreased by 75% and infant mortality by nearly 50% to 
43/1 000 within a few years.
The potential impact of the re-discovery and implementation of 
PHC is considerable, and there is no reason to delay starting. The 
involvement of (community) paediatricians can contribute to the 
process, but cannot substitute for a focused approach by the whole 
health team and the involvement of the community.
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Table 1. Health status indicators, Gelukspan Health Ward 
1978 - 1989
Indicator 1978 1985 1989
No. of children <5 years 9 000 13 500
Perinatal mortality rate 60/1 000 78/1 000 39/1 000
Infant mortality rate >200/1 000 41/1 000 24/1 000
<5 mortality rate 105/1 000 17/1 000 6/1 000
No. of paediatric deaths in 
hospital
144* 63 33
No. of visits to UFC/child <1/year 7/year
Total No. of visits to UFC 3 000 95 000 76 709
Home deliveries 75% 29% 15%
ANC visits 2 077 15 375 19 679
Supervised deliveries 684 2 554 2 981
Maternal mortality rate ? 180/100 000 50/100 000
Family planning visits 1 000 17 746
Health care worker/
population
1/7 000 1/1 000
Doctor/population 1/30 000 1/10 000
Midwife/population 1/12 000 1/2 500
* In 1979.
UFC = under-5 clinic; ANC = antenatal clinic.
